Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain
Pelthos Therapeutics Inc. (PTHS)
Company Research
Source: GlobeNewswire
First clinical trial conducted in human subjects to evaluate CT2000 for the treatment of both acute ocular pain and chronic ocular surface pain commonly associated with dry eye disease CT2000 is a lead pipeline asset of Channel Therapeutics, a Pelthos subsidiary DURHAM, N.C., March 31, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced that the first patient has been dosed in a Phase 1b/2a clinical trial evaluating CT2000 as a potential treatment for eye pain. Pelthos’ subsidiary Channel Pharmaceutical Corporation (“Channel”) owns the rights to CT2000 and its NaV1.7 inhibitor pipeline and is conducting the clinical work through its Australian subsidiary. "The successful dosing of the first patient is a meaningful step in advancing Channel’s pipeline of eye pain treatments,” said Scott Plesha, CEO of Pelthos. “While w
Show less
Read more
Impact Snapshot
Event Time:
PTHS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PTHS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PTHS alerts
High impacting Pelthos Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
PTHS
News
- Pelthos Therapeutics to Participate in Piper Sandler Spring Biopharma SymposiumGlobeNewswire
- Pelthos Therapeutics Announces CFO TransitionGlobeNewswire
- Pelthos Therapeutics Maps Public-Market Path, ZELSUVMI Surge, Adds Xepi and Xeglyze in Roth Interview [Yahoo! Finance]Yahoo! Finance
- Pelthos Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- Pelthos Therapeutics Inc (PTHS) Q4 2025 Earnings Call Highlights: Prescription Surge and ... [Yahoo! Finance]Yahoo! Finance
PTHS
Earnings
- 3/19/26 - Miss
PTHS
Sec Filings
- 4/14/26 - Form 8-K
- 4/10/26 - Form 8-K
- 4/6/26 - Form 4
- PTHS's page on the SEC website